利美尼定用于治疗创伤后颈源性头痛：病例系列
Use of Rimegepant in the Management of Cervicogenic Headache Secondary to Trauma: A Case Series.
作者信息
Zaw Shin T, Zaw Thinzar, Torres Benito
机构信息
Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, USA.
Medicine, University of Central Florida College of Medicine, Orlando, USA.
出版信息
Cureus. 2023 Feb 5;15(2):e34662. doi: 10.7759/cureus.34662. eCollection 2023 Feb.
Abstract
A cervicogenic headache (CH) originates from a cervical source. Multiple diagnostic criteria and treatment strategies for CH are present. Rimegepant is a calcitonin gene-related peptide receptor (CGRP) antagonist. We present a case series of three patients with CH who reported varying degrees of decreased headache intensity after using rimegepant.
摘要
颈源性头痛（CH）起源于颈部。目前有多种CH的诊断标准和治疗策略。瑞美吉泮是一种降钙素基因相关肽受体（CGRP）拮抗剂。我们报告了一组3例CH患者的病例系列，他们在使用瑞美吉泮后头痛强度均有不同程度的减轻。
Zotero 插件